We are submitting herewith the outcome of the Board meeting

Kilitch Drugs (India) Ltd. KI 6" November, 2026 To, To, The Manager - Corporate Relationship The Manager - Corporate Compliance Dept. National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot No.C-1, P. J. Towers, Dalal Street G Block, BKC, Bandra (E), Fort, Mumbai - 400 001 Mumbai 400 051 Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH Sub: Outcome of the Board Meeting Dear Sir, In continuation of our letter dated 2"? November, 2026 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, 6" November, 2026 have considered and approved the following; 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30" September, 2026. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference. The Board Meeting commenced at 16:30 hours and concluded at 20:30 hours. Request you to kindly take note of the same and acknowledge the receipt. Thanking you, Yours Faithfully, For Kilitch Drugs (India) Limited Digitally signed by MUKUND MUKUND PRATAPRAI MEHTA PRATAPRAI MEHTA. Date: 2026.11.06 20:33:15 +0530! Mukund Mehta Managing Director DIN: 00147876 oxo. 9001:2008 c 13485:2003 WHO CERTIFIED Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. ¢ Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. e CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 « E-mail : info@kilitch.com » Website : www.kilitch.com KILITCH DRUGS ( INDIA) LIMITED STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2026 Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com CIN:L24239MH1992PLC066718 (Rs. in Lakhs except Earnings per Share data) | z Th ree Months Ended Six Months Ended Year Ended| 30-09-2026 | 30-06-2026 30-09-20 25 | 30-09-2026 | 30-09-2025 | 31-03-2026 et L Sere ety ci. ty eee Unaudited Unaudited | Unaudited | Unaudited| Unaudited Audited 1 ee Net Sales/ Income from operations 4,349.26 4,091.20 3,781.35 8,440.46 7,193.55 18,857.43 Other Income 276.69 354.76 760,89 631.45 1,110.41 1,384.85 Total Income 4,625,95 4,445.96 4,542.24 9,071.91 8,303.96 20,242.28 2 =| Expenses | Cost of Materials Consumed 1,689.79 2,024.54 1,568.37 3,714.33 3,321.80 8,780.36 Changes in Inventories of Finished Goods, Work-in- Progress and Stock-in-Trade (60,08) (19.81) 206.90 (79.89) 130,61 106,73 Employee Benefit Expenses 430.75 352.50 328.25 783.25 567.74 1,233.50 | Finance Cost 153.80 48.63 67,86 202,43 126.52 244.31 Depreciation and Amortisation Expenses 344,43 75.86 52.70 420.30 102.57 228.80 _ Export Product Registration/Commission 550.12 519,77 527.11 1,069.89 1,077.61 2,139,01 | Other Expenses 914.89 749.66 783.66 1,664.55 1,371.33 3,354.20 Total Expenses 4,023.70 3,751.16 3,534.85 7,774.86 6,698.38 16,086.91 3 Profit / (Loss) before Exceptional items (1-2) 602.25 694.20 1.007.39 1,297.05 1,605.58 4,155.37 4 Exceptional Items : z Sea arlene : 5 Profit / (Loss) from ordinary activities before tax f (3+4) 602.25 694.80 1,007.39 1,297.05 1,605,58 4,155.37 6 Less: Tax Expenses:+ Current Tax 155.03 161.17 178,14 316.20 308.00 1,085.69 Deferred Tax | 37,03 28.38 (42.32) 65.41 (53.43); (170.28) 7 Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6) 410.19 505.24 871.57 915.44 1,351.01 3,239.96 8 Other Comprehensive Income (after tax) (133.31) 500.21 (229.86) 366.90 63.64 (106.50) 9 | Total Comprehensive Income (after taxes) (7+8) 276.88 1,005.46 641.71 | 1,282.34 | 1,414.65 3,133.46 10 Paid-Up equity share capital (Face Value Rs 10 per share} 3,496.16 3,496.16 1,748.08 3,496.16 1,748.08 3,496.16 11 | Other Equity 29,804.51 12 ‘|Earning per share (not annualised) (a) Basic 117 1.45 2.64 2.62 4.13 9.57 | ib) Diluted Mike 1.45 2.64 2.62 4.13 957 1. The above Unaudited Standalone Financial Results of the Company for the quarter and six months ended 30th September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th November, 2026. 2. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment, As such, there are no separate reporting segments as per Ind- ASLO8. 3. Proposed Conversion of Debt and Divestment of Subsidiary The Company has approved the conversion of its entire outstanding debt, including service costs, aggregating up to %57.00 crore, extended to) Kilitch Estro Biotech PLC ("KEB”), a material subsidiary incorporated in Ethiopia, into equity shares of KEB, subject to compliance with FEMA and other applicable laws, Further, the Company has approved the divestment of its entire shareholding in KEB, including additional shares arising from the aforesaid conversion, to HarmeeCare Pharmaceuticals, a state-owned public enterprise of the Oromia Regional State of Ethiopia, for an aggregate consideration of USD 14.00 million towards 100% shareholding and settlement of KEB's existing debts and liabilities, out of which USD 12.855 million shall be payable to the Company, The transaction is subject to applicable regulatory approvals and statutory compliances, 4. The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods, For and on behalf of thy Board Mukund Mehta f Managing Director Place : Mumbai DIN:- 00147876 Dated: 6th Nov, 2026 KILITCH DRUGS (INDIA) LIMITED STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER 2026 CIN:L24239MH1992PLC066718 (Rs, in Lakhs ) Peninsiers As at 30th Sept, 2026 As al 31st March, 2026 Unaudited Audited ASSETS Non-current assets + Property, Plant and Equipment 17,068.14 1,927,12 - Capital work-in-progress e 14,001.93 - Other Intangible Assets 25:75 26.41 Financial assets - Investments 7,830.92 7,189.06 - Loans/Advances 5,841.92 5,728.20 + Other Financial Assets 1.25 0.50 Deferred tax assets (Net) 392.52, 457,93 (A) 31,160.49 29,331.15 Current Assets - Inventories 1,222.09 1,152.07 Financial assets - Investrnents 5,082.92 5,196.33 - Trade Receivables 11,231.32 11,724.43 ~ Ca&s Chas h Equivalents 398,38 929.63 ~ Other Bank Balances 121,52 100.20 - Uther Financial Assets 1.80 3.25 Other Current Assets 1,676.90} 1,508.48 (B) 19,734.93 20,614.39 TOTAL ASSETS (A +B) 50,895.41 49,945.54 EQUITY AND LIABILITIES Equity - Equity Share Capital 3,496.16 3,496.16 - Other Equity 31,086.83 29,804.51 (a) 34,582.99 | __ 33,300.67 Liabilities Non-Current llablilities Financial Liabilities - Borrowings 5,665.93 5,860.35 Provisions 67,94 67.94 (8) 5,733.87 5,928.29 Current liabilities Financial Liabilities - Borrowings 3,965.43 2,977.62 - Trade Payables Micro and Small Enterprises Others 5,480.68 6,819.42 - Other Financial Liabilities 4.47 4.50 Provisions 295.98 221.87 Current Tax Liabilities [Net] 809.85 656.59 Other Current Liabilities Se ee ai oi ee | (¢) 10,578.55 10,716.59 TOTAL EQUITY AND LIABILITIES (A+B+C) 50,895.41 . 49,945.54 For aud ytif ehalf oft he ¢oard of Directors f Mukund ehta Place; Mumbai Managing Director Dated: 6th Nov, 2026 DIN: 00147876 KILITCH DRUGS ( INDIA) LIMITED UNAUDITED STANDALONE CASH FLOW STATEMENT FOR SIX MONTHS ENDED 30TH SEPTEMBER, 2026 CIN:L24239MH1992PLC066718 (Rs. in Lakhs } For t he Six months ended 30th September, | For Six Months Ended 30th September, asc | 2 [Showing first 8,000 characters — download PDF for full document]